Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations - Carlos Jimenez-Vicente; Aina Cardus; Sandra Castaño-Diez; Guillermo Ramil; Sara Garcia-Avila; Lucia Gomez-Perez; Daniel Esteban; Iago Arribas; Antonella Lucia Sturla; Monica Lopez-Guerra; Alexandra Martinez-Roca; Albert Cortes-Bullich; et al. (Blood Cancer Journal)